Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist
- 1 January 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 43 (15), 1089-1115
- https://doi.org/10.2165/00003088-200443150-00003
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Investigation of the Mutual Pharmacokinetic Interactions Between Bosentan, a Dual Endothelin Receptor Antagonist, and SimvastatinClinical Pharmacokinetics, 2003
- Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertensionExpert Opinion on Investigational Drugs, 2001
- Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transportEuropean Journal of Pharmaceutical Sciences, 2000
- Endothelin-receptor antagonists: current and future perspectivesDrug Discovery Today, 2000
- Hemodynamic Effects of Bosentan, an Endothelin Receptor Antagonist, in Patients With Pulmonary HypertensionCirculation, 2000
- Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Bosentan, an Endothelin Receptor Antagonist, in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 1999
- Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-GlycoproteinPharmaceutical Research, 1999
- Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacksPain, 1996
- Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failureThe Lancet, 1995
- The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary HypertensionThe New England Journal of Medicine, 1992